Arena Pharmaceuticals to Report Second Quarter 2007 Financial Results and to Host Conference Call and Webcast on Thursday, July 19, 2007
SAN DIEGO, July 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced it will report financial results for the second
quarter 2007 after the Nasdaq Global Market closes on Thursday, July 19, 2007.
That same afternoon, Jack Lief, Arena's President and Chief Executive Officer,
and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial
Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time) to discuss the financial results for the second quarter 2007 and
to provide a corporate update.
The conference call may be accessed by dialing 866.202.0886 for domestic
callers and 617.213.8841 for international callers. Please specify to the
operator that you would like to join the "Arena Second Quarter Earnings Call."
The conference call will be webcast live under the investor relations section
of Arena's website at http://www.arenapharm.com, and will be archived there
for 30 days following the call. Please connect to Arena's website several
minutes prior to the start of the broadcast to ensure adequate time for any
software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Arena's most advanced product candidate, lorcaserin, is
being investigated in a Phase 3 clinical trial program for the treatment of
obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled
receptors, an important class of validated drug targets, includes compounds
being evaluated independently and with its partners, Merck & Co., Inc. and
Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, preclinical and internal
and partnered clinical programs, and ability to develop compounds and
commercialize drugs. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or results may
differ materially from Arena's expectations. Factors that could cause actual
results to differ materially from the forward-looking statements include, but
are not limited to, Arena's planned clinical trials may not proceed at the
time Arena expects or at all, the results of preclinical studies or clinical
trials may not be predictive of future results, Arena's ability to partner
lorcaserin, APD125, APD791 or other of its compounds or programs, the timing,
success and cost of Arena's research, out-licensing endeavors and clinical
trials, Arena's ability to obtain additional financing, Arena's ability to
obtain and defend its patents, and the timing and receipt of payments and
fees, if any, from Arena's collaborators. Additional factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO, or David Walsey, Director,
Corporate Communications, both of Arena Pharmaceuticals, Inc.,
+1-858-453-7200, ext. 1682; or Mary Claire Duch, Media Relations, of WeissComm
Partners, +1-212-301-7228, for Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com